Novel Pretreatment Scoring Incorporating C-reactive Protein to Predict Overall Survival in Advanced Hepatocellular Carcinoma with Sorafenib Treatment Liver.

Slides:

Advertisements

Similar presentations

Intermediate stage HCC management

Advertisements

Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy : A Korean multicenter.

Echocardiographic Changes in Patients with Stage 3-5 Chronic Kidney Disease and Left Ventricular Diastolic Dysfunction Cardiorenal Med 2014;4:

Triple Negative Breast Cancer versus Non-Triple Negative Breast Cancer Treated with Breast Conservation Surgery Followed by Radiotherapy: A Systematic.

Public Health Genomics 2012;15:1–10 - DOI: /

Qualitative and Quantitative Issues of Lymph Nodes as Prognostic Factor in Colon Cancer Dig Surg 2013;30: DOI: / Fig. 1. Multiple.

Renalase, a Novel Enzyme Involved in Blood Pressure Regulation, Is Related to Kidney Function but Not to Blood Pressure in Hemodialysis Patients Kidney.

Fig. 3. Kaplan-Meier analyses of biochemical recurrence (BCR)-free survival rates according to ADCmeanvalues among the total subjects (A) and among the.

Am J Nephrol 2013;38: DOI: / Fig. 1. Study selection process.

Quantitative Analysis of Abdominal Aortic Calcification in CKD Patients Without Dialysis Therapy by Use of the Agatston Score Kidney Blood Press Res 2013;38:

The ART of Decision Making : Retreatment with Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma Wolfgang Sieghart, Florian Hucke,

The Clinical Significance of Uric Acid and Complement Activation in the Progression of IgA Nephropathy Kidney Blood Press Res 2016;41: DOI: /

Downregulation of MicroRNA-145 Caused by Hepatitis B Virus X Protein Promotes Expression of CUL5 and Contributes to Pathogenesis of Hepatitis B Virus-Associated.

Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study Liver Cancer.

BCLC Outperforms HKLC Staging of Hepatocellular Carcinoma in Multiethnic Asians – Real-World Perspective ESPS Manuscript NO:

Diabetic Cardiovascular Disease Predicts Chronic Kidney Disease Awareness in the Kidney Early Evaluation Program Cardiorenal Med 2011;1:45–52 - DOI: /

Metastatic Castration-Resistant Prostate Cancer: Two Case Reports of Dramatic Response with Abiraterone Acetate in Patients Heavily Pretreated with Chemotherapy.

Anti-Infective Locks for Treatment of Central Line-Associated Bloodstream Infection: A Systematic Review and Meta-Analysis Am J Nephrol 2011;34:415–422.

Volume 24, Issue 7, Pages (July 2016)

Oncol Res Treat 2016;39: DOI: /

The Role of Radical Prostatectomy and Radiotherapy in Treatment of Locally Advanced Prostate Cancer: A Systematic Review and Meta-Analysis Urol Int 2017;99:

Determinants of Overweight and Obesity in Lung Transplant Recipients

Baicalein, a Natural Anti-Cancer Compound, Alters MicroRNA Expression Profiles in Bel-7402 Human Hepatocellular Carcinoma Cells Cell Physiol Biochem 2017;41:1519–1531.

The Impact of Case Finding on the Recruitment Yield for COPD Research in Primary Care: An Observational Study Respiration 2016;92: DOI: /

Acta Haematol 2013;129:207– DOI: /

Figure 2 Disease-free survival in patients with normal versus high pretreatment C-reactive protein (CRP) levels. From: Elevated serum levels of C-reactive.

Evaluating Quality in Clinical Cancer Research: The M. D

Pulmonary Hypertension Is Associated with Mortality and Cardiovascular Events in Chronic Kidney Disease Patients Am J Nephrol 2017;45: DOI: /

Electrochemotherapy in the Treatment of Massive, Multisite Breast Cancer Metastasis to the Skin and Subcutaneous Tissue: A Case Report Breast Care 2016;11:

Elevated FOXC2 Expression Promotes Invasion of HCC Cell Lines and is Associated with Poor Prognosis in Hepatocellular Carcinoma Cell Physiol Biochem 2017;44:99–109.

Cell Physiol Biochem 2016;40: DOI: /

MicroRNAs for the Prediction of Early Response to Sorafenib Treatment in Human Hepatocellular Carcinoma Liver Cancer 2017;6: DOI: /

Volume 52, Issue 4, Pages (October 2007)

Level of α-Fetoprotein Predicts Mortality Among Patients With Hepatitis C–Related Hepatocellular Carcinoma Gia L. Tyson, Zhigang Duan, Jennifer R. Kramer,

Volume 72, Issue 5, Pages (November 2017)

Volume 66, Issue 2, Pages (August 2014)

Clinical Implications of C-Reactive Protein as a Prognostic Marker in Advanced Cancer Patients in Palliative Care Settings Koji Amano, MD, Isseki Maeda,

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic.

Adjuvant Dose-Dense Chemotherapy in Breast Cancer: Standard of Care in High-Risk Patients Breast Care 2016;11: DOI: / Fig. 1. Strategies.

Risk of de novo Hepatocellular Carcinoma after HCV Treatment with Direct-Acting Antivirals Liver Cancer - DOI: / Fig. 1. Flowchart of included.

Early Systolic Blood Pressure Changes in Incident Hemodialysis Patients Are Associated with Mortality in the First Year Kidney Blood Press Res 2012;35:663–670.

A Novel Prognostic Nomogram Accurately Predicts Hepatocellular Carcinoma Recurrence after Liver Transplantation: Analysis of 865 Consecutive Liver Transplant.

Cell Physiol Biochem 2016;39: DOI: /

Volume 152, Issue 8, Pages (June 2017)

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Staging Hepatocellular Carcinoma by a Novel Scoring System (BALAD Score) Based on Serum Markers Hidenori Toyoda, Takashi Kumada, Yukio Osaki, Hiroko.

Volume 145, Issue 1, Pages (July 2013)

A Pathological Scoring System to Predict Renal Outcome in Diabetic Nephropathy Am J Nephrol 2015;41: DOI: / Fig. 1. Renal survival.

Volume 68, Issue 1, Pages (January 2018)

Correction Journal of the American College of Surgeons

Targets for immunotherapy of liver cancer

Trends in the management and burden of alcoholic liver disease

Volume 57, Issue 4, Pages (October 2012)

Pretreatment Quality of Life Is an Independent Prognostic Factor for Overall Survival in Patients with Advanced Stage Non-small Cell Lung Cancer Yingwei.

Q.A. Truong et al. Circ Cardiovasc Qual Outcomes 2011;4:

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Impact of Lepidic Component Occupancy on Effects of Adjuvant Chemotherapy for Lung Adenocarcinoma Shinsuke Sasada, MD, PhD, Yoshihiro Miyata, MD, PhD,

Wolfgang Sieghart, Florian Hucke, Markus Peck-Radosavljevic

Gender differences in treatment outcomes of tuberculosis patients in Taiwan: a prospective observational study J.-Y. Feng, S.-F. Huang, W.-Y. Ting, Y.-C.

Molecular prognostication of liver cancer: End of the beginning

Is the B12/CRP Index More Accurate Than You at Predicting Life Expectancy in Advanced Cancer Patients? Filipa Tavares, MD Journal of Pain and Symptom.

Clinical Relevance of Our Multimodality Prognostic Score

Volume 70, Issue 4, Pages (April 2019)

Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular.

Hashem B. El-serag, Thomas Tran, James E. Everhart Gastroenterology

Neal S Goldstein, MD The Annals of Thoracic Surgery

Fig. 1. Kaplan-Meier curves for PFS and OS

Kaplan-Meier survival curve for CVD mortality among physically active and inactive type 2 diabetic patients stratified by baseline hs-CRP levels. Kaplan-Meier.

The SUV on 18F-FDG-PET/CT imaging as an independent predictor for overall survival and disease free survival after hepatectomy of Hepatocellular carcinoma（

Fig. 1. Classification of the Kaplan-Meier curves and Cox survival estimates for the OS of patients using the pSPC in Cohort_C and in the overall population.

Presentation transcript:

Novel Pretreatment Scoring Incorporating C-reactive Protein to Predict Overall Survival in Advanced Hepatocellular Carcinoma with Sorafenib Treatment Liver Cancer 2016;5:257-268 - DOI:10.1159/000449337 Fig. 1. OS of patients with advanced stage HCC treated with sorafenib stratified by baseline AFP and C-reactive protein (CRP). The Kaplan-Meier curve shows the OS stratified by (a) CRP [<1.0 vs. ≥1.0 mg/dL; MST =15.7 vs. 6.8 months (p=0.0067)], (b) AFP [<200 vs. ≥200 ng/mL; MST =24.1 vs. 8.0 months (p<0.0001)], (c) CRP [<1.0 vs. ≥1.0 mg/dL; MST =30.7 vs. 14.2 months (p=0.033)] in the subgroup of patients with AFP <200 ng/mL, and (d) CRP [<1.0 vs. ≥1.0 mg/dL; MST =9.2 vs. 3.8 months (p=0.057)] in the subgroup of patients with AFP ≥200 ng/mL. © 2016 S. Karger AG, Basel

Novel Pretreatment Scoring Incorporating C-reactive Protein to Predict Overall Survival in Advanced Hepatocellular Carcinoma with Sorafenib Treatment Liver Cancer 2016;5:257-268 - DOI:10.1159/000449337 Fig. 2. OS of patients with advanced stage HCC treated with sorafenib stratified by the proposed scoring system. This Kaplan-Meier plot shows the OS stratified by prognostic scores. The numbers of patients with prognostic scores of 0, 1, 2, 3, and 4 were 7, 22, 48, 59, and 29, respectively. The MSTs of patients with prognostic scores of 0, 1, 2, 3, and 4 were 2.4, 3.7, 9.0, 19.4, and 36.5 months, respectively. © 2016 S. Karger AG, Basel

Novel Pretreatment Scoring Incorporating C-reactive Protein to Predict Overall Survival in Advanced Hepatocellular Carcinoma with Sorafenib Treatment Liver Cancer 2016;5:257-268 - DOI:10.1159/000449337 Fig. 3. The patients with higher BCP scores had significantly better OS among patients with CLIP scores of 2 (p=0.0002). The OS of patients with prognostic scores of 1 or 2 v.s. 3 or 4 were 6.2 v.s. 19.4 months, respectively. CLIP 2=the Cancer of the Liver Italian Program score of 2. © 2016 S. Karger AG, Basel

Novel Pretreatment Scoring Incorporating C-reactive Protein to Predict Overall Survival in Advanced Hepatocellular Carcinoma with Sorafenib Treatment Liver Cancer 2016;5:257-268 - DOI:10.1159/000449337 Fig. 4. The patients with higher BCP scores had better OS among patients with CLIP scores of 3. That was marginally significant (p=0.057). The OS of patients with prognostic scores of 0 or 1 v.s. 2 or 3 were 3.5 v.s. 6.4 months, respectively. CLIP 3=the Cancer of the Liver Italian Program score of 3. © 2016 S. Karger AG, Basel